AIM
NTLA icon

Anchor Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Anchor Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40
Closed -$6.48K – 960
2021
Q2 		$6.48K Hold
40
– – ﹤0.01% 776
2021
Q1 		$3.21K Hold
40
– – ﹤0.01% 832
2020
Q4 		$2.18K Buy
+40
New +$1.45K ﹤0.01% 839

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Anchor Investment Management's NTLA Position: Q3 2021 in Review

Anchor Investment Management sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 40 shares — an estimated $6.48K sold.

Anchor Investment Management first reported a position in NTLA in Q4 2020 and held it in 3 quarters. The position peaked at $6.48K in Q2 2021. 364 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

  • Anchor Investment Management reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Anchor Investment Management sold 40 Intellia Therapeutics shares in Q3 2021, an estimated $6.48K.
  • Anchor Investment Management first reported a position in Intellia Therapeutics in Q4 2020 and held it in 3 quarters.
  • Anchor Investment Management's Intellia Therapeutics position peaked at $6.48K in Q2 2021.
  • 364 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Anchor Investment Management's 13F filing for Q3 2021, filed 2 Jan 2024.